drugset
drugset / Trial / NCT01034111

A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)

NCT01034111 ↗

Phase 3 Completed 30 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will assess, over a 4-week treatment period, the safety and efficacy of the addition of sitagliptin to metformin in participants with type 2 diabetes mellitus (T2DM) who failed to achieve glycemic control on metformin monotherapy.

Timeline

Start
2010-03-01
Primary completion
2010-10-04
Completion
2010-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitagliptin Small molecule 100 mg Oral
Background Metformin Small molecule 1000 mg Oral

Indications

type 2 diabetes mellitus